Can radiation before brain surgery stop cancer spread?
NCT ID NCT07802353
First seen Sep 03, 2026 · Last updated Sep 09, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether giving a precise, high-dose radiation treatment called stereotactic radiosurgery (SRS) before surgery to remove a brain tumor can prevent cancer cells from spreading to other parts of the brain during the operation. The study enrolls adults with brain metastases from breast, lung, melanoma, or gastrointestinal cancers who are scheduled for surgery to remove one tumor. Participants receive SRS to that tumor, followed by standard surgery within a few weeks. The researchers track whether this approach reduces complications and improves outcomes compared to usual care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Stereotactic radiosurgery (SRS) given before surgical removal of a brain tumor
- What this could lead to
- If it works, this approach could reduce the risk of cancer spreading in the brain after surgery, leading to fewer complications and better outcomes for people with brain metastases.
- What could go wrong
- This is a small, early-phase study, so results may not apply to everyone. There is also a risk of radiation-related side effects, such as brain tissue damage, and the treatment may not prevent all spread.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2026
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically or cytologically confirmed breast cancer, non-small cell lung cancer, melanoma, or gastrointestinal cancer. In malignancies for which tissue confirmation is not standard diagnostic practice (for example, hepatocellular carcinoma diagnosed by characteristic imaging), radiographic diagnosis consistent with standard of care is acceptable. In all cases, the intracranial lesion planned for resection undergoes pathologic examination as part of protocol-directed surgery. * At least one intact brain metastasis is planned for surgical resection that has not previously received stereotactic radiosurgery or other focal radiotherapy, measuring 6 cm or less in diameter. * No evidence of leptomeningeal disease based on clinical symptoms, MRI imaging of the brain or spinal cord, and/or lumbar puncture cytologic analysis. * No prior SRS to the index BM planned for surgical resection. Prior SRS to non- index lesions is permitted, with approval from the principal investigator. The interval since prior cranial radiotherapy will be recorded. All clinically significant toxicities from prior radiotherapy must have resolved to grade 1 or lower (CTCAE); patients with unresolved symptomatic (grade 2 or higher) radiation necrosis, treatment-related enhancing treatment effect, or clinically significant cerebral edema attributable to prior cranial radiation are not eligible. * No prior therapeutic craniotomy or craniectomy with biopsy. * Age ≥ 18 * Karnofsky Performance Status (KPS) of ≥ 70 and anticipated survival of \>1 year * Ability to undergo contrast-enhanced MRI brain Exclusion Criteria: * Pregnant and/or breastfeeding * Prior whole brain radiotherapy. * Neurologic instability despite medical management, such that either the treating team or study investigators feel that urgent craniotomy without awaiting SRS is indicated. * Judgment by the principal investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Brain metastasases are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
7 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITINGRockville Centre, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
RECRUITINGCommack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain surgery gets a GPS: network maps may help remove tumors while preserving function
- Timing is everything: new study seeks best sequence for brain metastases treatment
- Massive study tests yearly brain scans for lung cancer patients
- New combo attack on aggressive breast cancer brain tumors shows promise in early trial
- MRI-Guided radiation shows promise for brain tumors in new trial
- Spinal tap could spot hidden brain cancers